^
    Apply
    A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) (NCT00759785)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    08/15/2018
    Initiation :
    09/30/2008
    Primary completion :
    02/17/2010
    Completion :
    02/17/2010
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR negative
    |
    dalotuzumab (MK 0646)
    Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) (NCT00614393)
    Phase 2
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    08/08/2018
    Initiation :
    12/24/2007
    Primary completion :
    06/01/2010
    Completion :
    03/07/2012
    KRAS
    |
    KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression
    |
    Erbitux (cetuximab) • irinotecan • dalotuzumab (MK 0646)
    A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) (NCT01234857)
    Phase 2
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    05/31/2017
    Initiation :
    09/17/2010
    Primary completion :
    10/15/2013
    Completion :
    10/15/2013
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    exemestane • Taltorvic (ridaforolimus) • dalotuzumab (MK 0646)
    Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008) (NCT00729742)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    04/04/2016
    Initiation :
    02/01/2009
    Primary completion :
    06/01/2010
    Completion :
    05/01/2011
    EGFR
    |
    EGFR mutation • EGFR amplification
    |
    erlotinib • dalotuzumab (MK 0646)